-
Cubist Announces Positive Results from Two Phase 2 Trials, CXA-201 and CDAD Program
Thursday, June 16, 2011 - 7:10am | 123Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections in adults. Based on these...
-
Goldman Sachs Raises PT On Pharmasset To $125
Thursday, June 16, 2011 - 6:18am | 26Goldman Sachs has raised the price target on Pharmasset (NASDAQ: VRUS) from $77 to $125 and maintains its Neutral rating.
-
Stocks to Watch for 6/16/11: Fresh 52-Week Highs and Lows
Thursday, June 16, 2011 - 2:28am | 2229The following stocks hit new 52-week highs in Wednesday's trading session 1) Ulta Salon, Cosmetics & Fragrances (NASDAQ: ULTA): Shares of Ulta hit a 52-week high of $59.40 in Wednesday's trading session. The stock closed at $57.03. The year-to-date performance of Ulta has been a gain of 67.7...
-
Options Brief: Exact Sciences Corporation
Wednesday, June 15, 2011 - 3:42pm | 87Shares of Exact Sciences Corporation (NASDAQ: EXAS) are lower on the session by 2.42%, trading at $7.26. Overall call volume is now running at 4.24x the daily average, with 57% of all calls traded being purchases on the offer. 1,031 contracts have traded on the session so far. Exact Sciences...
-
Benzinga's Top Downgrades
Wednesday, June 15, 2011 - 10:33am | 77Analysts at Auriga downgraded Myriad Genetics Inc (NASDAQ: MYGN) from “buy” to “hold.” MYGN's shares closed at $24.19 yesterday. Myriad Genetics' PEG ratio is 2.24. Analysts at Ardour Capital downgraded Capstone Turbine Corporation (NASDAQ: CPST) from “buy” to “accumulate.” CPST's shares closed at...
-
Benzinga's Volume Movers
Wednesday, June 15, 2011 - 10:31am | 174Universal Stainless & Alloy Products Inc (NASDAQ: USAP) shares surged 5.60% to $33.01 at 10:30 am. The volume of USAP shares traded was 461% higher than normal. USAP announced its plans to buy the assets of Patriot Special Metals of North Jackson, Ohio, for around $104.5 million NetApp Inc (...
-
Stocks Hitting 52-Week Highs
Wednesday, June 15, 2011 - 10:22am | 147Fundtech Ltd (NASDAQ: FNDT) shares rose 1.23% to create a new 52-week high of $20.53. FNDT announced a cash dividend of $0.10 per share for June. Pharmacyclics Inc (NASDAQ: PCYC) shares gained 0.33% to create a new 52-week high of $8.91. PCYC had $54.41 million in total cash and no debt for the...
-
Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study
Wednesday, June 15, 2011 - 9:05am | 83Cardium Therapeutics (NYSE: CXM) today announced that it has received clearance from the Russian Ministry of Health and Social Development to commence a Phase 3 registration study for the Company's Generx biologic product candidate. Generx is a new and innovative DNA-based angiogenic therapy...
-
Auriga Downgrades Myriad Genetics to Hold, Reduces PT to $25
Wednesday, June 15, 2011 - 8:52am | 105Auriga downgraded its rating on Myriad Genetics (NASDAQ: MYGN) from Buy to Hold. At the same time, Auriga reduced its price target on the company's stock from $27 to $25. In a research report published today, Auriga still maintains a positive view of the company's performance. In the report,...
-
Rodman & Renshaw Maintains Market Perform on Cell Therapeutics
Wednesday, June 15, 2011 - 8:10am | 112Rodman & Renshaw is out with its report today on Cell Therapeutics (NASDAQ: CTIC), maintaining Market Perform. In a note to clients, Rodman & Renshaw writes, "We are maintaining our Market Perform / Speculative Risk rating for Cell Therapeutics. The recent meeting with the FDA and...
-
Peregrine Reports Promising 12.4 Month Overall Survival Data From Phase II Trial in Non-Small Cell Lung Cancer
Wednesday, June 15, 2011 - 8:03am | 215Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported promising median overall survival (MOS) of 12.4 months from a Phase II clinical trial evaluating bavituximab plus carboplatin and paclitaxel in patients with previously untreated, locally-advanced or metastatic non-small cell lung cancer...
-
Auriga Downgrades Myriad Genetics To Hold, Lowers PT To $25
Wednesday, June 15, 2011 - 7:06am | 27Auriga has downgraded Myriad Genetics (NASDAQ: MYGN) from Buy to Hold and has lowered the price target from $27 to $25.
-
Rodman & Renshaw Provides Color on Prana Biotechnology, Market Outperform
Wednesday, June 15, 2011 - 6:31am | 130Rodman & Renshaw provided color on Prana Biotechnology (NASDAQ: PRAN) after a meeting with Professor Ashley Bush. In a research report published today, Rodman & Renshaw states, "We value Prana shares based on a universe of a comparable company analysis. We believe that Prana could be...
-
ImmunoGen Earns Milestone with BAY 94-9343 IND Submission
Tuesday, June 14, 2011 - 4:02pm | 163ImmunoGen, Inc. (Nasdaq: IMGN) today announced that Bayer HealthCare Pharmaceuticals' submission of an Investigational New Drug application for the TAP compound, BAY 94-9343, triggers a $2 million milestone payment to ImmunoGen. BAY 94-9343 is in development by Bayer HealthCare under an...
-
Tuesday's Put/Call Ratio Leaders
Tuesday, June 14, 2011 - 12:18pm | 80Here are today's put/call ratio leaders… 1. USEC Inc. (NYSE: USU) 20,822 puts, 54 calls 2. Gran Tierra Energy Inc. (NYSE: GTE) 3,200 puts, 10 calls 3. Tidewater Inc. (NYSE: TDW) 2,650 puts, 12 calls 4. Pharmacyclics Inc. (NASDAQ: PCYC) 9,769 puts, 96 calls 5. MGIC Investment Corp. (NYSE: MTG) 4,...